Abstract:Background: PD-L1 expression in tumor microenvironment of HCC was reported to associate with tumor aggressiveness and recurrence. The impact of sorafenib treatment on PD-L1 expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) of HCC has been unclear. Patients and Methods: We reviewed patients with HCC who had received sorafenib for advanced diseases at National Taiwan University Hospital, Taipei, Taiwan. Patients with paired HCC tissues, obtained before and after sorafenib treatment, were included. Immunohistochemistry (IHC) assay with clone SP142 antibody (Spring Bioscience, Pleasanton, CA, USA) was performed to analyze PD-L1 expression on TC and IC in paired specimens obtained before and after sorafenib. PD-L1 expression was scored as IHC 0, 1, 2, or 3 if Results: Twenty-three advanced HCC patients (Male: Female= 20: 3, median age of 64 years) with paired HCC tissues were included. All of the post-sorafenib HCC tissues were obtained after disease progression. The median duration of sorafenib treatment was 4.3 months (range: 1.3 to 18.7). The PD-L1 expression on IC was significantly increased in post-sorafenib HCC tissues, compared with tissues obtained before sorafenib (pre-sorafenib vs post-sorafenib IHC 0/1/2/3: 10/5/5/3 vs 5/5/2/11, p=0.046). However, the PD-L1 expression on TC was not significantly different between pre- and post-sorafenib tissues (IHC 0/1/2/3: 19/2/0/2 vs 14/5/0/4, p=0.065). By using IHC staining of CD68, CD66b, CD11b, and CD3 on the consecutive slides, we found the PD-L1-expressing IC were mainly CD68-positive macrophages, but not neutrophils or T lymphocytes. Neither the PD-L1 expression levels on IC of pre-sorafenib or those of post-sorafenib tissues were associated with OS or duration of sorafenib treatment. Conclusions: The PD-L1 expression on IC, especially on macrophages, in tumor microenvironment was significantly increased in post-sorafenib progression HCC tissues. Whether this increased PD-L1 expression contributes to treatment failure of sorafenib warrants further investigation (This work was supported by the grants of NTUH 105-M3232 and MOST 105-2314-B-002-180). Citation Format: Li-Chun Lu, Yi-Hsuan Lee, Chun-Jung Chang, Yu-Yun Shao, Tsung-hao Liu, Ann-Lii Cheng, Chih-Hung Hsu. Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1636. doi:10.1158/1538-7445.AM2017-1636

High Serum Spd-L1 Level Predicts Poor Outcome in Hepatocellular Carcinoma Patients Treated with Radiotherapy

High Serum Spd-1 and Spd-L1 Levels 1 Predict Outcome in Hepatocellular Carcinoma Patients Treated with Radiotherapy.

Higher Serum Spd-L1 Levels after Radiotherapy Indicate Poor Outcome in Hepatocellular Carcinoma Patients

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

Soluble PD-L1 As a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients with EGFR Mutations.

P2.01-30 Hepatitis B Infection or Aminotransferase Increase Associate with Poor Outcome of Anti-PD-1 Monotherapy in Patients with Advanced NSCLC

Pre-treatment Serum Levels of Soluble Programmed Cell Death-Ligand 1 Predict Prognosis in Patients with Hepatitis B-related Hepatocellular Carcinoma

Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization

Body Mass Index and Serum Alpha-Fetoprotein Level Associated with PD1 Expression and Prognosis in Patients with Hepatocellular Carcinoma

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors

Increased Expression Of Programmed Death-Ligand 1 (Pd-L1) On Infiltrating Immune Cells Of Hepatocellular Carcinoma (Hcc) Tissues After Sorafenib Treatment

Characterization of PD-L1 Protein Expression and CD8+ Tumor-Infiltrating Lymphocyte Density, and Their Associations with Clinical Outcome in Small-Cell Lung Cancer.

Soluble Programmed Death-Ligand 1 Indicate Poor Prognosis in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization

Abstract 1636: Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment

Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization – Implications in treatment outcomes

Clinical Significance of PD-1/PD-Ls Gene Amplification and Overexpression in Patients with Hepatocellular Carcinoma.

Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study

C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients

Increased Serum Type I Interferon Level May Predict Outcome in Hepatocellular Carcinoma Patients Treated with Radiotherapy

Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.